Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 9/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CCL2 | P13500 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10748557 | 0.79 | MEN1 (0.46) | APPCYP2C9TSHRCA1CA2 | |
| SCHEMBL15300858 | 0.78 | SLC6A4 (0.39) | APPSLC6A4 | |
| SCHEMBL9451240 | 0.77 | PPARG (0.46) | — | |
| SCHEMBL255656 | 0.77 | SLC6A4 (0.41) | APPSLC6A4CA1CA2CA9 | |
| SCHEMBL8048952 | 0.77 | KMT2A (0.47) | CYP2C9TSHRBRD4CCL2CYP3A4 | |
| SCHEMBL15140535 | 0.77 | PPARG (0.43) | SLC6A4CYP2C9TSHR | |
| SCHEMBL1847856 | 0.76 | ALDH1A1 (0.44) | SLC6A4TSHR | |
| SCHEMBL17091472 | 0.74 | ESR2 (0.48) | APP | |
| SCHEMBL1547544 | 0.72 | MAPT (0.47) | — | |
| SCHEMBL28772088 | 0.70 | PARP10 (0.41) | APPSLC6A4CYP2C9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158782-B2 | Biomolecule labeling reactants based on azacycloalkanes and conjugates derived thereof | WALLAC OY (FI) | 2012-04-17 | — | — | US | disclosed |
| US-20090156801-A1 | BIOMOLECULE LABELING REACTANTS BASED ON AZACYCLOALKANES AND CONJUGATES DERIVED THEREOF | NXP B.V. (NL) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156801-A1 | BIOMOLECULE LABELING REACTANTS BASED ON AZACYCLOALKANES AND CONJUGATES DERIVED THEREOF | DNMT1, PTMS, DNMT3A | APP 2686/4885SLC6A4 4673/4885CYP2C9 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.